Cargando empresa
Just reported
Q4 FY2026 results
From Cencora's results release of 4 de noviembre de 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Revenue
Actual
88,35B US$
+5,5 % y/y
+4,2 % q/qGuided
—
No guide given
EPS, GAAP
Actual
2,71 US$
-31 % q/q
Guided
—
No guide given
Operating income, GAAP
Actual
906,8M US$
-19 % q/q
Guided
—
No guide given
Company outlook
Full year 2027
- EPS, adjusted19,40 US$ – 19,75 US$First given
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.
The full earnings report →Keep exploring
The themes Cencora is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Medical Distribution
Graded A or B and worth $2B or more: A first, then the largest.
All 11 graded companies in its industry
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 oct 2026CBGraded C, now B
MCKMckesson Corporation4 nov 2026BAGraded B, now A
CVSCVS Health Corp4 nov 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 nov 2026BAGraded B, now A
BIIBBiogen Inc.28 oct 2026BAGraded B, now A
Estados financieros completos →
Construido a partir de los propios informes de Cencora, Inc. ante la Comisión de Bolsa y Valores de EE. UU. (SEC). Las cifras son las declaradas, con el historial por acción reexpresado a la base de acciones de hoy. Esto describe un negocio: no es asesoramiento de inversión ni una recomendación de compra o venta.
